Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Pain

Study type: Observational

Funder types: Industry

Identifiers

NCT02651363

CN003-001

Details and patient eligibility

About

The purpose of this study is to collect adverse events and identify risk factors in patients that are taking Dolocordralan Extra 25® and Dolocordralan Extra Forte®

Enrollment: 374 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are prescribed Dolocordralan Extra 25 and Dolocordralan Extra Forte at any of the participating clinics
• Patients who sign the informed consent form
• Patients who agree to comply with the study procedures

Exclusion criteria

• Please see the protocol for further information on exclusion criteria

Trial design

374 participants in 1 patient group

Patients treated with Dolocordralan